Literature DB >> 3976802

Natural course of retinitis pigmentosa over a three-year interval.

E L Berson, M A Sandberg, B Rosner, D G Birch, A H Hanson.   

Abstract

Ninety-four patients, 6 to 49 years old, with progressive forms of retinitis pigmentosa were examined at baseline and annually for three consecutive years with respect to visual acuity, kinetic visual fields, dark-adaptation thresholds, computer-averaged electroretinograms, and fundus photographs. A subset was recalled within two months of a given visit to measure intervisit variability and to develop criteria for what constitutes significant (P less than .01) functional change. Over a three-year interval full-field electroretinograms declined significantly in 66 of 86 patients (77%) with detectable responses at baseline. Patients lost an average of 16% to 18.5% of remaining electroretinographic amplitude per year and 4.6% of remaining visual field area per year. Bone spicule pigmentation increased in 41 of 76 patients for whom we could make comparisons over a three-year interval (54%). Visual acuity and dark-adaptation thresholds remained relatively stable.

Entities:  

Mesh:

Year:  1985        PMID: 3976802     DOI: 10.1016/0002-9394(85)90351-4

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  87 in total

1.  Null RPGRIP1 alleles in patients with Leber congenital amaurosis.

Authors:  T P Dryja; S M Adams; J L Grimsby; T L McGee; D H Hong; T Li; S Andréasson; E L Berson
Journal:  Am J Hum Genet       Date:  2001-03-29       Impact factor: 11.025

2.  Treatment with taurine, diltiazem, and vitamin E retards the progressive visual field reduction in retinitis pigmentosa: a 3-year follow-up study.

Authors:  Herminia Pasantes-Morales; Hugo Quiroz; Octavio Quesada
Journal:  Metab Brain Dis       Date:  2002-09       Impact factor: 3.584

3.  Slowing the degenerative process, long lasting effect of hyperbaric oxygen therapy in retinitis pigmentosa.

Authors:  Enzo Maria Vingolo; Monica Rocco; PierLuigi Grenga; Serena Salvatore; Paolo Pelaia
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-03       Impact factor: 3.117

4.  Visual acuity and perimacular retinal layers detected by optical coherence tomography in patients with retinitis pigmentosa.

Authors:  Toshihiko Matsuo; Noriko Morimoto
Journal:  Br J Ophthalmol       Date:  2007-02-21       Impact factor: 4.638

Review 5.  [Retinitis pigmentosa - a review. Pathogenesis, guidelines for diagnostics and perspectives].

Authors:  D Zobor; E Zrenner
Journal:  Ophthalmologe       Date:  2012-05       Impact factor: 1.059

6.  Relationship between foveal cone structure and clinical measures of visual function in patients with inherited retinal degenerations.

Authors:  Kavitha Ratnam; Joseph Carroll; Travis C Porco; Jacque L Duncan; Austin Roorda
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-08-28       Impact factor: 4.799

7.  Test-retest, within-visit variability of Goldmann visual fields in retinitis pigmentosa.

Authors:  Ava K Bittner; Mian Haris Iftikhar; Gislin Dagnelie
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-10-11       Impact factor: 4.799

8.  Retinal degeneration in children: dark adapted visual threshold and arteriolar diameter.

Authors:  Ronald M Hansen; Susan E Eklund; Ilan Y Benador; Julie A Mocko; James D Akula; Yao Liu; M Elena Martinez-Perez; Anne B Fulton
Journal:  Vision Res       Date:  2007-08-31       Impact factor: 1.886

9.  ABCA4 disease progression and a proposed strategy for gene therapy.

Authors:  Artur V Cideciyan; Malgorzata Swider; Tomas S Aleman; Yaroslav Tsybovsky; Sharon B Schwartz; Elizabeth A M Windsor; Alejandro J Roman; Alexander Sumaroka; Janet D Steinberg; Samuel G Jacobson; Edwin M Stone; Krzysztof Palczewski
Journal:  Hum Mol Genet       Date:  2008-12-12       Impact factor: 6.150

10.  ERGs, cone-isolating VEPs and analytical techniques in children with cone dysfunction syndromes.

Authors:  John P Kelly; Michael A Crognale; Avery H Weiss
Journal:  Doc Ophthalmol       Date:  2003-05       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.